Emily Hinchcliff1, Anca Chelariu-Raicu2, Shannon N Westin1. 1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2. Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
Abstract
PURPOSE OF REVIEW: To highlight relevant strategies to overcome poly(ADP-ribose) polymerase (PARP) inhibitor resistance and present key clinical trials. RECENT FINDINGS: The use of PARP inhibition (PARPi) for frontline maintenance offers substantial clinical benefit in patients with homologous recombination-deficient tumors. However, expanding PARPi from recurrent therapy to frontline maintenance may potentially result in more PARPi resistant tumors earlier in the treatment continuum and data for the use of PARPi after PARPi remain limited. Clinical evidence demonstrates tumors may develop resistance to PARPi through demethylation of the BRCA promoter or BRCA reversion mutations. Multiple clinical trials investigating therapeutic strategies to overcome resistance, such as combinations of PARPi with antiangiogenic drugs, PI3K/AKT/mTOR, or MEK inhibitors have already been reported and more are ongoing. Furthermore, increasing the amount of DNA damage in the tumor using chemotherapy or cell cycle inhibitors such as ATM, ATR/CHK1/WEE1 is also under exploration. SUMMARY: There is increasing clinical interest to identify options to enhance PARPi efficacy and overcome adaptive resistance. PARPi represent a class of drugs that have significantly impacted the treatment and maintenance of ovarian cancer; as the use of PARPi increases, better understanding of resistance mechanisms is essential.
PURPOSE OF REVIEW: To highlight relevant strategies to overcome poly(ADP-ribose) polymerase (PARP) inhibitor resistance and present key clinical trials. RECENT FINDINGS: The use of PARP inhibition (PARPi) for frontline maintenance offers substantial clinical benefit in patients with homologous recombination-deficient tumors. However, expanding PARPi from recurrent therapy to frontline maintenance may potentially result in more PARPi resistant tumors earlier in the treatment continuum and data for the use of PARPi after PARPi remain limited. Clinical evidence demonstrates tumors may develop resistance to PARPi through demethylation of the BRCA promoter or BRCA reversion mutations. Multiple clinical trials investigating therapeutic strategies to overcome resistance, such as combinations of PARPi with antiangiogenic drugs, PI3K/AKT/mTOR, or MEK inhibitors have already been reported and more are ongoing. Furthermore, increasing the amount of DNA damage in the tumor using chemotherapy or cell cycle inhibitors such as ATM, ATR/CHK1/WEE1 is also under exploration. SUMMARY: There is increasing clinical interest to identify options to enhance PARPi efficacy and overcome adaptive resistance. PARPi represent a class of drugs that have significantly impacted the treatment and maintenance of ovarian cancer; as the use of PARPi increases, better understanding of resistance mechanisms is essential.
Authors: Panagiotis A Konstantinopoulos; William T Barry; Michael Birrer; Shannon N Westin; Karen A Cadoo; Geoffrey I Shapiro; Erica L Mayer; Roisin E O'Cearbhaill; Robert L Coleman; Bose Kochupurakkal; Christin Whalen; Jennifer Curtis; Sarah Farooq; Weixiu Luo; Julia Eismann; Mary K Buss; Carol Aghajanian; Gordon B Mills; Sangeetha Palakurthi; Paul Kirschmeier; Joyce Liu; Lewis C Cantley; Scott H Kaufmann; Elizabeth M Swisher; Alan D D'Andrea; Eric Winer; Gerburg M Wulf; Ursula A Matulonis Journal: Lancet Oncol Date: 2019-03-14 Impact factor: 41.316
Authors: Kathleen N Moore; Angeles Alvarez Secord; Melissa A Geller; David Scott Miller; Noelle Cloven; Gini F Fleming; Andrea E Wahner Hendrickson; Masoud Azodi; Paul DiSilvestro; Amit M Oza; Mihaela Cristea; Jonathan S Berek; John K Chan; Bobbie J Rimel; Daniela E Matei; Yong Li; Kaiming Sun; Katarina Luptakova; Ursula A Matulonis; Bradley J Monk Journal: Lancet Oncol Date: 2019-04-01 Impact factor: 41.316
Authors: Mansoor Raza Mirza; Elisabeth Åvall Lundqvist; Michael J Birrer; Rene dePont Christensen; Gitte-Bettina Nyvang; Susanne Malander; Maarit Anttila; Theresa L Werner; Bente Lund; Gabriel Lindahl; Sakari Hietanen; Ulla Peen; Maria Dimoula; Henrik Roed; Anja Ør Knudsen; Synnöve Staff; Anders Krog Vistisen; Line Bjørge; Johanna U Mäenpää Journal: Lancet Oncol Date: 2019-08-29 Impact factor: 41.316
Authors: Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro Journal: N Engl J Med Date: 2018-10-21 Impact factor: 91.245
Authors: M A Vollebergh; E H Lips; P M Nederlof; L F A Wessels; M K Schmidt; E H van Beers; S Cornelissen; M Holtkamp; F E Froklage; E G E de Vries; J G Schrama; J Wesseling; M J van de Vijver; H van Tinteren; M de Bruin; M Hauptmann; S Rodenhuis; S C Linn Journal: Ann Oncol Date: 2010-12-06 Impact factor: 32.976
Authors: Kyle C Strickland; Brooke E Howitt; Sachet A Shukla; Scott Rodig; Lauren L Ritterhouse; Joyce F Liu; Judy E Garber; Dipanjan Chowdhury; Catherine J Wu; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos Journal: Oncotarget Date: 2016-03-22
Authors: Marilyne Labrie; Tae-Beom Kim; Zhenlin Ju; Sanghoon Lee; Wei Zhao; Yong Fang; Yiling Lu; Ken Chen; Pedro Ramirez; Michael Frumovitz; Larissa Meyer; Nicole D Fleming; Anil K Sood; Robert L Coleman; Gordon B Mills; Shannon N Westin Journal: Oncotarget Date: 2019-05-28
Authors: Timothy A Yap; Rebecca Kristeleit; Vasiliki Michalarea; Stephen J Pettitt; Joline S J Lim; Suzanne Carreira; Desamparados Roda; Rowan Miller; Ruth Riisnaes; Susana Miranda; Ines Figueiredo; Daniel Nava Rodrigues; Sarah Ward; Ruth Matthews; Mona Parmar; Alison Turner; Nina Tunariu; Neha Chopra; Heidrun Gevensleben; Nicholas C Turner; Ruth Ruddle; Florence I Raynaud; Shaun Decordova; Karen E Swales; Laura Finneran; Emma Hall; Paul Rugman; Justin P O Lindemann; Andrew Foxley; Christopher J Lord; Udai Banerji; Ruth Plummer; Bristi Basu; Juanita S Lopez; Yvette Drew; Johann S de Bono Journal: Cancer Discov Date: 2020-06-12 Impact factor: 38.272